
    
      This is a prospective, multicenter, open label study, to evaluate the safety, tolerability
      and efficacy of OTX-TIC intracameral implant in subjects with primary open-angle glaucoma or
      ocular hypertension. The subjects will be followed for approximately 7 months (one-month
      washout and 6 months follow-up after injected of the OTX-TIC implant).
    
  